Hughes Steven George 4

Accession 0001599901-25-000150

CIK 0001599901other

Filed

Aug 7, 8:00 PM ET

Accepted

Aug 8, 5:39 PM ET

Size

26.0 KB

Accession

0001599901-25-000150

Form 4

Period: 2025-08-06

Chief Medical Officer

Transactions

Sale
Common Stock
2025-08-06$42.74/sh−33,983$1,452,342→ 38,867 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-08-06−11,283→ 73,342 total
Exercise: $15.96Exp: 2032-02-13→ Common Stock (11,283 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-08-06−12,334→ 52,417 total
Exercise: $6.57Exp: 2033-09-10→ Common Stock (12,334 underlying)
Exercise/Conversion
Common Stock
2025-08-06$15.96/sh+11,283$180,077→ 84,133 total
Sale
Common Stock
2025-08-06$42.74/sh−11,283$482,205→ 72,850 total
Exercise/Conversion
Common Stock
2025-08-06$6.57/sh+12,334$81,034→ 85,184 total
Exercise/Conversion
Common Stock
2025-08-06$10.16/sh+17,667$179,497→ 90,517 total
Sale
Common Stock
2025-08-06$42.74/sh−17,667$755,040→ 72,850 total
Exercise/Conversion
Common Stock
2025-08-06$22.47/sh+6,167$138,572→ 79,017 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-08-06−17,667→ 75,083 total
Exercise: $10.16Exp: 2034-01-19→ Common Stock (17,667 underlying)
Sale
Common Stock
2025-08-06$42.74/sh−6,167$263,561→ 72,850 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-08-06−6,167→ 74,000 total
Exercise: $22.47Exp: 2033-01-19→ Common Stock (6,167 underlying)
Sale
Common Stock
2025-08-06$42.74/sh−12,334$527,122→ 72,850 total

Footnotes (6)

[F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024.
[F2]This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.15 to $46.44. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]This option was granted on February 14, 2022 and vests in equal installments of 5,652 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on February 14, 2026.
[F4]This option was granted on September 11, 2023 and vests in equal installments of 1,542 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on September 11, 2027.
[F5]This option was granted on January 20, 2023 and vests in equal installments of 3,083 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2027.
[F6]This option was granted on January 20, 2024 and vests in equal installments of 2,208 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2028.

Documents

1 file

Avidity Biosciences, Inc.

CIK 0001599901

Entity typeother